| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T52 |
0-265 |
Sentence |
denotes |
Evaluate and care for patients with COVID‐19 for liver disease Prioritize for COVID‐19 testing: (1) patients with cirrhosis, (2) patients with CLD receiving immunosuppressive medications, and (3) patients with new‐onset encephalopathy or other acute decompensation |
| T53 |
266-304 |
Sentence |
denotes |
Regularly monitor liver biochemistries |
| T54 |
305-427 |
Sentence |
denotes |
Consider non‐COVID‐19 etiologies for liver disease: (1) exacerbation of preexisting CLD or (2) drug‐induced hepatotoxicity |
| T55 |
428-477 |
Sentence |
denotes |
Use acetaminophen 2 g/day as preferred medication |
| T56 |
478-528 |
Sentence |
denotes |
Use nonsteroidal anti‐inflammatory drugs as needed |
| T57 |
529-656 |
Sentence |
denotes |
Consult the University of Liverpool document to assess possible drug interactions Follow WHO guidelines for COVID‐19 diagnosis |
| T58 |
657-714 |
Sentence |
denotes |
Consider NAFLD as a prognostic factor for severe COVID‐19 |
| T59 |
715-762 |
Sentence |
denotes |
Screen patients for hepatitis B surface antigen |
| T60 |
763-846 |
Sentence |
denotes |
Consider HBV prophylaxis prior to use of anti‐IL‐6, other immunosuppressive therapy |
| T61 |
847-896 |
Sentence |
denotes |
Monitor liver function tests of patients with CLD |
| T62 |
897-937 |
Sentence |
denotes |
Be alert to possible drug hepatotoxicity |
| T63 |
938-1017 |
Sentence |
denotes |
Decompensated CLD and ALT >5 times ULD contraindications for remdesivir therapy |
| T64 |
1018-1177 |
Sentence |
denotes |
Prioritize persons with CLD for clinical trials Test for COVID‐19 patients with acute decompensation or acute‐on‐chronic liver and per institution’s practices |
| T65 |
1178-1256 |
Sentence |
denotes |
Persons with NAFLD likely to have comorbidity risk factors for severe COVID‐19 |
| T66 |
1257-1331 |
Sentence |
denotes |
Consider patients with CLD/COVID‐19 for early admission and clinical trial |
| T67 |
1332-1379 |
Sentence |
denotes |
Use acetaminophen (2–3 g/day is generally safe) |
| T68 |
1380-1429 |
Sentence |
denotes |
Limit use of nonsteroidal anti‐inflammatory drugs |
| T69 |
1430-1540 |
Sentence |
denotes |
Test for COVID‐19 patients with acute decompensation or acute‐on‐chronic liver and per institution’s practices |
| T70 |
1541-1619 |
Sentence |
denotes |
Persons with NAFLD likely to have comorbidity risk factors for severe COVID‐19 |
| T71 |
1620-1694 |
Sentence |
denotes |
Consider patients with CLD/COVID‐19 for early admission and clinical trial |
| T72 |
1695-1742 |
Sentence |
denotes |
Use acetaminophen (2–3 g/day is generally safe) |
| T73 |
1743-1792 |
Sentence |
denotes |
Limit use of nonsteroidal anti‐inflammatory drugs |
